know the proliferative activity of a tumour in choosing an adequate therapeutic method and predicting the prognosis of the disease. To know the growth fraction of cancers. various techniques. including the 3H-thymidine labelling index (Bleiberg & Galana. 1976 : Sasaki. 1977 . BrdU labelling index (Gratzner. 1982) . flow cytometric analysis (Barlogie et al.. 1983 : Shutte et al.. 1987 : Volm et al.. 1988 . positive rate (Gerdes et al.. 1983 (Gerdes et al.. : 1984 and DNA polvmerase x positive cell rate have been used. DNA polymerase a. the most important enzyme in DNA replication (Sarngadharan et al.. 1978 : Weissbach. 1979 
Results
Immunohistochemicallv stained monoclonal antibody against DNA polymerase a was distributed in tumour cell nuclei ( Figure 1 ). There are no tumour cells with cytoplasmic staining. The rates of DNA polymerase a positive cells for the 63 resected specimens ranged from 24.0% to 74.60/O (mean 4488%: SD 9.4%). The DNA polymerase a positive cell rates of biopsy and resected specimens taken from the same tumours were compared. An intimate correlation was found between the two kinds of specimens from 13 of the patients (r = 0.872. P <0.001) (Figure 2 ).
To find the grade of malignancy. the tumours were divided into two groups by the DNA polymerase a positive cell rates. Tumours with a DNA polymerase a positive cell rate of > 42% were designated as high growth fraction. and those with a DNA polymerase a positive cell rate of <42%. as low growth fraction. There was no significant correlation between the DNA polymerases a positive cell rates and the histological type. tumour size. invasion of bowel wall. lymphatic invasion. venous invasion. lymph node metastases. or peritoneal metastasis (Table I) . Liver metastases were observed in 11 (34.400) of 32 patients with high growth fraction tumours. and four (12.9%) of 31 with low growth fraction tumours (Table I ). There was a significant difference in liver metastases between the twso groups of patients (P <0.05).
During the follow-up period of 1-4 vears. 10 (31.300) patients with high grow-th fraction tumours died of their disease. compared with two (6.50°) of patients with low growth fraction tumours. Figure 3 (Table II) .
In other words. it is important to know the proliferative activity pre-operatively in choosing an adequate therapeutic method and predicting the prognosis. We tried to compare the growth fractions of biopsy and resected specimens by use of a monoclonal antibody against DNA polymerase a. There is a good correlation between the DNA polymerase a positive cell rates of the two groups. Regarding intratumoural heterogeneity of growth fraction, it is possible to avoid overlooking small clones of tumour cells by taking several biopsy specimens from separate areas. We therefore came to the conclusion that it would be possible to analyse preoperatively the proliferative activity detected in several biopsy specimens by use of a monoclonal antibody against DNA polymerase a.
From the findings, it may be concluded that the detection of growth fraction by use of a monoclonal antibody against DNA polymerase x pre-operatively enables the measurement of proliferative activity in biopsy specimens. and that the growth fraction of colorectal tumours is a useful indicator in projecting the prognosis. Tumours with a high growth fraction run poor prognoses and it is advisable. therefore. to perform intensive postoperative therapy for such tumours because the chemosensitivity of tumours is related to the ratio of proliferating cells. 
